Globe Newswire (Mon, 16-Mar 8:03 AM ET)
Immutep Halts Pivotal Lung Cancer Trial After Futility Review, Extends Cash Runway
TipRanks (Mon, 16-Mar 6:28 AM ET)
Analysts Conflicted on These Healthcare Names: Immutep (IMMP) and Ultragenyx Pharmaceutical (RARE)
TipRanks (Sat, 14-Mar 12:20 PM ET)
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early
Benzinga (Fri, 13-Mar 1:23 PM ET)
Morning News Wrap-Up 3/13/26: Friday’s Biggest Stock Market Stories!
TipRanks (Fri, 13-Mar 12:41 PM ET)
Why Did Investors Lose Faith In Immutep Stock (IMMP) Today?
TipRanks (Fri, 13-Mar 8:11 AM ET)
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
Globe Newswire (Fri, 13-Mar 8:00 AM ET)
Immutep (IMMP) was downgraded to a Hold Rating at Robert W. Baird
TipRanks (Fri, 13-Mar 6:55 AM ET)
Immutep halts late-stage trial for lead asset after efficacy analysis
Seeking Alpha News (Fri, 13-Mar 6:53 AM ET)
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Globe Newswire (Fri, 6-Feb 8:00 AM ET)
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Immutep Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol IMMP.
As of March 16, 2026, IMMP stock price declined to $0.47 with 5,347,501 million shares trading.
IMMP has a beta of 2.41, meaning it tends to be more sensitive to market movements. IMMP has a correlation of 0.05 to the broad based SPY ETF.
IMMP has a market cap of $68.49 million. This is considered a Micro Cap stock.
In the last 3 years, IMMP traded as high as $3.90 and as low as $.43.
The top ETF exchange traded funds that IMMP belongs to (by Net Assets): IBB.
IMMP has underperformed the market in the last year with a price return of -73.4% while the SPY ETF gained +22.6%. IMMP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -82.0% and -83.4%, respectively, while the SPY returned -1.6% and -2.5%, respectively.
IMMP support price is $.47 and resistance is $.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMMP shares will trade within this expected range on the day.
